HomeCompareMDP vs ABBV

MDP vs ABBV: Dividend Comparison 2026

MDP yields 45.09% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $73.9K in total portfolio value· pulled ahead in Year 4
10 years
MDP
MDP
● Live price
45.09%
Share price
$59.07
Annual div
$26.63
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.5K
Annual income
$6.37
Full MDP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MDP vs ABBV

📍 ABBV pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDP
Annual income on $10K today (after 15% tax)
$3,832.63/yr
After 10yr DRIP, annual income (after tax)
$5.41/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,050.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDP + ABBV for your $10,000?

MDP: 50%ABBV: 50%
100% ABBV50/50100% MDP
Portfolio after 10yr
$65.4K
Annual income
$12,389.07/yr
Blended yield
18.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MDP
Analyst Ratings
3
Buy
9
Hold
Consensus: Hold
Altman Z
1.4
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDP buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDPABBV
Forward yield45.09%3.06%
Annual dividend / share$26.63$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$28.5K$102.3K
Annual income after 10y$6.37$24,771.77
Total dividends collected$5.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: MDP vs ABBV ($10,000, DRIP)

YearMDP PortfolioMDP Income/yrABBV PortfolioABBV Income/yrGap
1$12,954$2,254.49$11,550$430.00+$1.4KMDP
2$15,226$1,364.75$13,472$627.96+$1.8KMDP
3$17,041$749.56$15,906$926.08+$1.1KMDP
4← crossover$18,626$392.02$19,071$1,382.55$445.00ABBV
5$20,130$200.23$23,302$2,095.81$3.2KABBV
6$21,641$101.12$29,150$3,237.93$7.5KABBV
7$23,206$50.80$37,536$5,121.41$14.3KABBV
8$24,856$25.45$50,079$8,338.38$25.2KABBV
9$26,609$12.74$69,753$14,065.80$43.1KABBV
10$28,478$6.37$102,337$24,771.77$73.9KABBV

MDP vs ABBV: Complete Analysis 2026

MDPStock

Meredith Corporation operates as a diversified media company primarily in the United States. It operates in two segments, National Media and Local Media. The National Media segment offers national consumer media brands through various media platforms, including print magazines, digital and mobile media, brand licensing activities, database-related activities, affinity marketing, and business-to-business marketing products and services. It publishes media in entertainment, food, lifestyle, parenting, and home categories, such as People, Better Homes & Gardens, InStyle, Allrecipes, Real Simple, Shape, Southern Living, Martha Stewart Living, and other brands, as well as 300 special interest publications under approximately 70 brands. This segment operates approximately 50 Websites and applications. It is also involved in the brand licensing, affinity marketing, third-party marketing, consumer database, and other related operations, as well as provision of magazine advertising and circulation, digital and customer relationship marketing, other custom publishing project, and ancillary products and services. In addition, this segment operates The Foundry 360, a creative content studio, which develops content marketing programs across various platforms comprising native advertising that enable clients to engage new consumers and build long-term relationships with existing customers for a range of industries. The Local Media segment operates approximately 17 television stations that include 7 CBS affiliates, 5 FOX affiliates, 2 MyNetworkTV affiliates, 1 NBC affiliate, 1 ABC affiliate, and 2 independent stations. It also includes 12 Websites and 12 applications focused on news, sports, and weather-related information. In addition, this segment sells geographic and demographic-targeted digital and print advertising programs to third parties. The company was founded in 1902 and is headquartered in Des Moines, Iowa.

Full MDP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MDP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDP vs SCHDMDP vs JEPIMDP vs OMDP vs KOMDP vs MAINMDP vs JNJMDP vs MRKMDP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.